N

NewLimit Tech Stack

Epigenetic reprogramming therapies to treat age-related disease

Biotechnology Research South San Francisco, California 11–50 employees Founded 2022 Privately Held

NewLimit is a biotech startup (founded 2022, 11–50 employees) developing medicines that restore regenerative capacity in aging cells by reprogramming the epigenome. The tech stack—Python, NumPy, SciPy, Pandas, R across AWS/GCP/Azure—reflects a research-heavy operation running large-scale genomic screening. Hiring skews 9 senior roles across research (8 positions) with only 2 engineering and 1 data hire, indicating a biology-first stage where computational scaling and automation of wet-lab workflows (single-cell perturbation screens, LNP production, viral vector transduction) remain painful bottlenecks.

Tech Stack 12 technologies

Core StackPython NumPy Pandas AWS Docker Unix RT-qPCR SciPy GCP Azure Singularity R

What NewLimit Is Building

◆Challenges

Timely data delivery
Scaling pooled single cell perturbation screens
Logistical bottlenecks in preclinical development
Pipeline efficiency improvement
Manual effort reduction
Scaling single cell experiments
Automation of molecular biology protocols
Scaling lnp production
Optimizing downstream processing
Establishing robust production protocols

▲Active Projects

Screen epigenetic reprogramming interventions for aged t cells
Single-cell perturbation screen pipelines
Large-scale single cell perturbation experiments
Microservice web applications for data flow
Lnp formulation and downstream processing
Primary and secondary analysis software
Preclinical development of reprogramming medicines
Regulatory filing for ind and ctns
Develop functional assays for endothelial decline
Viral vector transduction

Hiring Activity

Accelerating10 roles · 5 in 30d

Department

Research

8

Engineering

2

Data

1

Ops

1

Seniority

Senior

9

Mid

2

Director

1

Notable leadership hires: Head of Translation, Director of Operations

Company intelligence

Find more companies like NewLimit by tech stack, pain points and active projects

Get started free

About NewLimit

NewLimit develops epigenetic reprogramming medicines targeting age-related diseases by restoring function in aged and diseased cells. The company uses functional genomics, pooled perturbation screening, and machine learning to identify and validate therapeutic targets at scale. Active projects span early-stage biology (primary and secondary analysis software, functional assays for endothelial decline), process development (LNP formulation and downstream processing, viral vector work), and regulatory preparation (IND and CTA filings). The organization is headquartered in South San Francisco and currently focuses on U.S.-based hiring.

HeadquartersSouth San Francisco, California

Company Size11–50 employees

Founded2022

Hiring MarketsUnited States

Frequently Asked Questions

What is NewLimit's technology platform?

NewLimit develops epigenetic reprogramming therapies using functional genomics, pooled perturbation screening, and machine learning to treat age-related diseases by restoring regenerative potential in aged cells.